Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolyticallysensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-

like coronaviruses

Javier A. Jaimes ¹, Nicole M. André ¹, Jean K. Millet ² and Gary R. Whittaker ^{1*}

¹ Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca NY 14853 USA

² Virologie et Immunologie Moléculaires, INRAE, Université Paris-Saclay, 78352 Jouy-en-Josas, France

* Corresponding author: grw7@cornell.edu

Abstract

The 2019 novel coronavirus (2019-nCoV) is currently causing a widespread outbreak centered on Hubei province, China and is a major public health concern. Taxonomically 2019-nCoV is closely related to SARS-CoV and SARS-related bat coronaviruses, and it appears to share a common receptor with SARS-CoV (ACE-2). Here, we perform structural modeling of the 2019-nCoV spike glycoprotein. Our data provide support for the similar receptor utilization between 2019-nCoV and SARS-CoV, despite a relatively low amino acid similarity in the receptor binding module. Compared to SARS-CoV, we identify an extended structural loop containing basic amino acids at the interface of the receptor binding (S1) and fusion (S2) domains, which we predict to be proteolytically-sensitive. We suggest this loop confers fusion activation and entry properties more in line with MERS-CoV and other coronaviruses, and that the presence of this structural loop in 2019-nCoV may affect virus stability and transmission.

Introduction

Coronaviruses are zoonotic pathogens that are well known to evolve environmentally and infect many mammalian and avian species (Menachery et al., 2017). These diverse viruses often have effective transmission and immune evasion strategies, especially when outbreaks occur within dense human populations. In the past two decades, coronavirus outbreaks have arisen in human populations around the world, each unique but also with similarities. Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 in Guangdong province, China causing an outbreak that spread to 26 countries, with more than 8,000 infections and 774 deaths and a case fatality rate of 9.5% (WHO, 2004). More recently, the ongoing Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak that originated in 2012 in Saudi Arabia has spread to 27 countries with 2,494 infections and 858 deaths, with a case fatality rate of 34.4% (WHO, 2019). The recent surfacing of the novel coronavirus 2019-nCoV (first identified on December 12th, 2019) was initially detected in Wuhan, Hubei Province, China, and as of January 30th, 2020 has spread globally via travelers and has breached the boundaries of 29 countries (Lu et al., 2020). There has been a guarantine on Wuhan, China since January 23 -24th, 2020, along with travel restrictions between China and the rest of the world, in an attempt to prevent a global pandemic (Zhou et al., 2020a). Within the 33 provinces of China, as of January 30th, 2020 there have been more than 9,000 suspected cases, with more than 5,900 confirmed cases and 106 fatalities as of January 28th, 2020 with a case fatality rate of 2-3% (Lu et al., 2020). However, the number of cases and deaths have been increasing daily since the outbreak started, and at the time this manuscript was submitted (Feb 9th, 2020), 37,592 cases and 814 fatalities have been reported (Johns Hopkins University, 2019). Similar to SARS-CoV and MERS-CoV, 2019-nCoV infections were observed in family clusters and hospital personnel (Chan et al., 2020; Gralinski and Menachery, 2020; Lu et al., 2020; Phan et al., 2020). The outbreak occurring during the winter is another commonality between SARS-CoV and 2019-nCoV (Zhou et al., 2020a).

Clinical signs associated with 2019-nCoV include pneumonia, fever, dry cough, headache and dyspnea which may progress to respiratory failure and death (Gralinski and Menachery, 2020; Huang et al., 2020; Zhou et al., 2020a). The incubation period for 2019-nCoV seems to be longer than for SARS-CoV and MERS-CoV, which have a mean incubation time of 5 to 7 days leading to challenges in contact tracing (Wu et al., 2020). Preexisting conditions and comorbidities such as hypertension, diabetes, cardiovascular disease or kidney disease affect the severity of pathogenesis attributed to SARS-CoV and MERS-CoV, and MERS-CoV, and thus far similar patterns seem to exist with 2019-nCoV (Gralinski and Menachery, 2020; Huang et al., 2020). SARS-CoV and MERS-CoV seem to exhibit deleterious morbidity and mortality on the elderly population (>60 years of age), with 26 deaths in this age group, and 2019-nCoV is currently portraying a comparable trend (Gralinski and Menachery, 2020). In a study of the first 425 patients in Wuhan, China, the median age of the patients was 59 years; there were no cases in children less than 15 years of age and only a single report of a positive RT-PCR test on sputum in an asymptomatic 10 year old male within a family cluster infection (Chan et al., 2020).

The coronaviruses belong to the *Coronaviridae* family and the *Orthocoronaviridae* subfamily, which is divided in four genera; *Alphacoronavirus, Betacoronavirus, Gammacoronavirus,* and *Deltacoronavirus.* SARS-CoV, MERS-CoV, and 2019-nCoV are all betacoronaviruses, a genus that includes many viruses that infect humans, bats, and other wild animals (ICTV, 2018). Betacoronaviruses have many similarities within the ORF1ab polyprotein and most structural proteins, however, the spike protein and accessory proteins portray significant diversity (Cui et al., 2019). MERS-CoV has maintained a stable genome since its emergence in 2012, unlike other coronaviruses that readily evolve and can undergo notable recombination events (Perlman, 2020).

Alphacoronaviruses and betacoronaviruses have mostly been thought to have originated in bats; this includes SARS-CoV, MERS-CoV and 2019-nCoV, as well as other human coronaviruses such as HCoV-NL63 (Cui et al., 2019; Huynh et al., 2012; Perlman, 2020). Gammacoronaviruses and deltacoronaviruses are reported to have an avian origin, but are known to infect both mammals and avian species (Woo et al., 2012). Human infections of bat-origin viruses typically occur through intermediate hosts; for SARS-CoV these hosts are palm civets (*Paguma larvata*) and racoon dogs (*Nyctereutes procyonoides*), and for MERS-CoV the known host is the dromedary camel (*Camelus dromedarius*) (Cui et al., 2019; Xu et al., 2009). SARS-CoV antibodies were first detected in palm civets and the animal handlers in wet markets (Cui et al., 2019). MERS-CoV is thought to have been circulating for at least 30 years within the dromedary camel population based on retrospective antibody testing of serum from 1983 (Cui et al., 2019). The source of the

2019-nCoV outbreak has been reported to be linked to the Huanan seafood wholesale market in Wuhan, where the CDC confirmed that 43 (22%) of the 198 cases had visited the market (Li et al., 2020). The market sells many species including seafood, birds, snakes, marmots and bats (Gralinski and Menachery, 2020). The market was closed on January 1st, 2020 and sampling and decontamination have occurred in order to find the source of the infection. Origination of 2019-nCoV from bats has been strongly supported, but the presumed intermediate host remain to be identified; initial reports that 2019-nCoV had an origin in snakes have not been verified (Gralinski and Menachery, 2020; Zhou et al., 2020a).

The coronavirus spike protein (S) is the primary determinant of viral tropism and is responsible for receptor binding and membrane fusion. It is a large (approx. 180 kDa) glycoprotein that is present on the viral surface as a prominent trimer, and it is composed of two domains, S1 and S2 (Belouzard et al., 2012). The S1 domain mediates receptor binding, and is divided into two subdomains, with the N-terminal domain often binding sialic acid and the C-domain binding a specific proteinaceous receptor (Hulswit et al., 2016). The receptor for SARS-CoV has been identified as angiotensin converting enzyme 2 (ACE2), similar to what has been recently identified with 2019nCoV (Cui et al., 2019; Hoffmann et al., 2020; Zhou et al., 2020a). HeLa cells expressing or not human, Chinese horseshoe bat, mouse, civet, and pig ACE2 were infected and 2019-nCoV was able to use all receptors except mouse ACE2 (Zhou et al., 2020a). 2019-nCoV was also found not to use dipeptidyl peptidase 4 (DPP4), the receptor for MERS-CoV (Cui et al., 2019; Hoffmann et al., 2020; Zhou et al., 2020a). Following receptor binding, the S2 domain mediates viralmembrane fusion through the exposure of a highly conserved fusion peptide (Lai et al., 2017; Madu et al., 2009). The fusion peptide is activated through proteolytic cleavage at a site immediately upstream (S2'), which is common to all coronaviruses. In many (but not all) coronaviruses, additional proteolytic priming occurs at a second site located at the interface of the S1 and S2 domains (S1/S2) (Millet and Whittaker, 2015). The use of proteases in priming and activation, combined with receptor binding and ionic interactions (e.g. H⁺ and Ca²⁺) together control viral stability and transmission, and also control the conformational changes in the S protein that dictate the viral entry process into host cells (Belouzard et al., 2012; Heald-Sargent and Gallagher, 2012; Lai et al., 2017). Specifically, SARS-CoV and MERS-CoV both infect type II pneumocytes in vivo, however they individually infect ciliated bronchial epithelial cells and nonciliated bronchial epithelial cells receptively (Cui et al., 2019). Similar to SARS-CoV and MERS-CoV, 2019-nCoV can infect ex vivo with the same range of cell culture lines, e.g. Vero E6, Huh-7 cells (Hoffmann et al., 2020). However primary human airway epithelial cells have been reported to be the preferential cell type for 2019-nCoV (Perlman, 2020; Zhu et al., 2020). Overall, how cell tropism of 2019-nCoV reflects a balance of receptor binding, endosomal environment and protease activation, and the specifics of this mechanisms remain to be determined.

The rapid dissemination and sharing of information during the 2019-nCoV outbreak has surpassed that of both MERS-CoV or SARS-CoV, where the latter virus was only identified after several months and with a genome available a month later (Gralinski and Menachery, 2020). The 2019-nCoV was identified and a genome sequence was available within a month from the initial surfacing of the agent in patients (Gralinski and Menachery, 2020). Initial reports identified that 2019-nCoV contains six major open reading frames in the viral genome and various accessory proteins (Zhou et al., 2020a). The SARS-like virus Bat-CoV RaTG13 was observed to have highly homologous conservation of the genome, with two other bat SARS-like viruses (Bat-SL-CoVZC45 and Bat-SL-CoVZXC21) having 89-97% sequence identity (Gralinski and Menachery, 2020). The S protein of 2019-nCoV was found to be approximately 75% homologous to the SARS-CoV spike (Gralinski and Menachery, 2020; Zhou et al., 2020a).

In this study, we perform bioinformatic analyses and homology structural modeling of 2019-nCoV S, in comparison with closely related viruses. We identify a small structural loop at the S1/S2 interface that contains a short insert containing two arginine residues for 2019-nCoV S. These features are missing from all other SARS-CoV-related viruses, but present in MERS-CoV S and in many other coronaviruses. We discuss the importance of this extended basic loop for S protein-mediated membrane fusion and its implications for viral transmission.

Results

<u>Comparison of amino acid identity of the spike (S) protein of 2019-nCoV with human SARS-CoV</u> To obtain an initial assessment of shared and/or specific features of the 2019-nCoV spike (S) envelope glycoprotein, a protein sequence alignment was performed to compare the sequence of the Wuhan-Hu-1 strain of the novel coronavirus with that of the closely related human SARS-CoV S strain Tor2 sequence (Supplementary Fig. 1). The overall percent protein sequence identity found by the alignment was 76% (Fig. 1A). A breakdown of the functional domains of the S protein, based on the SARS-CoV S sequence, reveals that the S1 receptor-binding domain was less conserved (64% identity) than the S2 fusion domain (90% identity). Within S1, the N-terminal domain (NTD) was found to be less conserved (51% identity) compared to the receptor binding domain (RBD, 74% identity). The relatively high degree of sequence identity for the RBD is consistent with the view that 2019-nCoV, like SARS-CoV, may use ACE2 as its host cell receptor, as for SARS-CoV (Hoffmann et al., 2020; Wan et al., 2020; Zhou et al., 2020a). Interestingly, when the more defined receptor binding motif (RBM) was analyzed (*i.e.* the region of SARS-CoV S containing residues that were shown to directly contact the ACE2 receptor) the identity between the two sequences drops to 50%, in this case hinting at possible differences in binding residues involved in the interaction with the receptor and/or binding affinities (Li et al., 2005; Wan et al., 2020). As expected, within the well-conserved S2 domain, subdomain identities were high for the fusion peptide region (FP, 93% identity), high for the heptad-repeat 1 region (HR1, 88% identity), identical for HR2 (100% identity) and high for both the transmembrane and the C-terminal endodomain (TM, 93% identity and E, 97% identity).

Phylogenetic analysis of 2019-nCoV S with other betacoronaviruses

Early phylogenetic studies on 2019-nCoV genomic sequences revealed that it clustered closely with sequences originating from SARS-like sequences from bats, within lineage B of the *Betacoronavirus* genus. Lineage A groups prototypical coronaviruses such as murine hepatitis virus (MHV) and human coronaviruses HCoV-HKU1 and HCoV-OC43 (Fig. 1B). The other highly pathogenic coronavirus, MERS-CoV is found within lineage C, along with related camel-derived MERS-CoV. Lineage C also groups viruses from bats and other mammals such as hedgehogs. Lineage D contains viral species infecting bats. To gain a better understanding of both shared and specific features of 2019-nCoV S protein, a phylogenetic analysis centered on S protein sequences

of representatives of the four *Betacoronavirus* lineages was carried out (Fig. 1B). Fifteen sequences of 2019-nCoV S sequences obtained from NCBI and GISAID from China and various export locations world-wide were analyzed along with representative members of lineages A-D betacoronaviruses. The analysis confirmed that all 2019-nCoV S sequences clustered very closely with bat SARS-like sequences, with the closest matching sequence corresponding to a bat coronavirus (bat-CoV) strain named Bat-SL-RaTG13. Other closely related sequences found were from Bat-SL-CoVZC45 and Bat-SL-CoVZXC21. The sub-clade that groups 2019-nCoV, Bat-SL-RaTG13, Bat-SL-CoVZC45 and Bat-SL-CoVZXC21 is distinct from the one grouping human and civet SARS-CoV along with other related bat SARS-like viruses, such as Bat-SL-LYRa3.

Alignments of RBD and cleavage sites of 2019-nCoV and other bat-CoVs

An S protein sequence alignment focusing on the RBD region of 2019-nCoV, SARS-CoV and bat-SARS-related viruses reveals that the N-terminal half of the RBD is relatively well conserved whereas the C-terminal half, which contains the RBM, exhibits more variations (Fig. 2A). Notably, Bat-SL-CovZC45 and Bat-SLCoVZXC2 both have two deletions of 5 and 14 residues within the RBD. The composition of residues found at the two known coronavirus S cleavage sites was performed using alignment data (Fig. 2B and C). The region around arginine 667 (R667) of SARS-CoV S, the S1/S2 cleavage site aligned well with 2019-nCoV and the bat SARS-related sequences (Belouzard et al., 2009). Notably, an arginine at the position corresponding to SARS-CoV R667 is conserved for the other five sequences analyzed. The alignment shows that 2019-nCoV contains a four amino acid insertion ₆₈₁PRRA₆₈₄ that is not found in any other sequences, including the closely related bat-SL-RaTG13 (Fig. 2B). Together with the conserved R685 amino acid found in 2019nCoV at the putative S1/S2 cleavage site, the insertion introduces a stretch of three basic arginine residues that could potentially be recognized by members of the pro-protein convertase family of proteases (Seidah, 2011; Seidah et al., 2013). This insertion was conserved for all fifteen 2019nCoV sequences analyzed (Supplementary Fig. 2). Within the Betacoronavirus genus, the presence of a basic stretch of residues at the S1/S2 site is found for a number of species from lineages A (HCoV-HKU1, MHV, HCoV-OC43) and C (MERS-CoV, BatCoV-HKU5). The four amino acid insertion feature appears unique among lineage B viruses, as all other species analyzed in the extended alignment, none contained the stretch of basic residues identified in 2019-nCoV S (Supplementary Fig. 2). As expected from previous analyses, the S2' cleavage site, located immediately upstream of the fusion peptide and corresponding to the residue position R797 in the case of SARS-CoV, was strictly conserved for 2019-nCoV and closely related bat SARS-related sequences (Fig. 2C). Of note, the leucine (L) residue found at position 792 of the SARS-CoV sequence is substituted to serine (S) residue for 2019-nCoV S as well as the bat SARS-related sequences. The fusion peptide sequence was found to be well conserved for all sequences analyzed.

2019-nCoV S protein homology structure modeling

To gain a deeper understanding of common and possibly distinguishing features found in 2019nCoV S protein, homology structure modeling was undertaken. The analysis of modeled proteins provides a powerful tool to identify predicted structural characteristics, that can translate into structure-function changes in of the studied protein. Our laboratory has taken advantage of these tools in the past, for structure-function studies of other CoVs S proteins (Belouzard et al., 2012; Jaimes et al., 2020; Jaimes and Whittaker, 2018). To perform the modeling, it is first necessary to identify the protein structure to be used as template, which will determine the accuracy of the predicted model. The S protein structure of several CoVs including: Alphacoronavirus: HCoV-NL63 and feline coronavirus UU4 (FCoV-UU4); Betacoronavirus: HCoV-HKU1, MHV, SARS-CoV and MERS-CoV; Gammacoronavirus: infectious bronchitis virus (IBV); and Deltacoronavirus: porcine deltacoronavirus (PDCoV) have been reported previously (Kirchdoerfer et al., 2016; Shang et al., 2018; Shang et al., 2017; Walls et al., 2016a; Walls et al., 2016b; Yang et al., 2020; Yuan et al., 2017). Considering that genome and S protein alignments have showed that the 2019-nCoV belongs to the Betacoronavirus genus, we focused our analysis on the S structures from viruses belonging to this genus. To select the template structure, the S protein amino acid sequences from four representative betacoronaviruses (HCoV-HKU1, MHV, SARS-CoV and MERS-CoV) were aligned and the solved S protein structures were compared to determine their amino acid identity and the overall structural organization similarities among these proteins (Supplementary Fig. 3A). We observed an average of ~30% identity among the four viral S proteins at the amino acid level, with the exception of HCoV-HKU1 and MHV which share an amino acid identity of 59% at the S protein (Supplementary Fig. 3A). Despite the differences at the amino acid level, the overall structure of the four Betacoronavirus S proteins showed a similar folding pattern (Supplementary Fig. 3B), and major differences can only be spotted at specific sections of the functional domains where flexible loops are abundant (e.g. RBD and cleavage sites). Considering this, we built a first set of models for the 2019-nCoV S protein based on each of the above-mentioned structures (Supplementary Fig. 4). Interestingly, we found no major differences at the secondary structures among the 2019-nCoV S protein predicted models depending on the S structure that was used as template for the modeling construction. However, extended flexible loops at the RBD and/or clashes between S monomers at the S2 domain level were observed in the 2019-nCoV S models based on HCoV-HKU1, MHV and MERS-CoV (Supplementary Fig. 4 – first three panels). In contrast, the predicted 2019-nCoV S model based on the SARS-CoV S structure displayed a much better organized folding and no major clashes were observed between the S monomers (Supplementary Fig. 4 – last panel).

As we described previously, the identity between 2019-nCoV and SARS-CoV at the S protein amino acid level was 76%, and the phylogenetic analysis grouped the 2019-nCoV in the lineage A of the Betacoronavirus genus, closely relating to SARS-CoV, as well as to other CoVs originated in bats (Fig. 1B). These two considerations, in addition to our preliminary modeling results, suggested SARS-CoV S as the most suitable template for modeling the 2019-nCoV S protein. Taking an alternative approach, the S protein sequence of 2019-nCoV was submitted to two structure homology modeling servers (Phyre 2 http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index and RaptorX http://raptorx.uchicago.edu). For both cases the structural models with highest homology scores were based on the SARS-CoV S template structure (PDB ID 5X58, data not shown), confirming the choice of using SARS-CoV S as template for generating structural models of 2019-nCoV.

To better compare the predicted structural characteristics of the 2019-nCoV, we also performed homology modeling of four S proteins from Bat-CoVs belonging to lineage B in our phylogenetic analysis, that showed to be closely related to 2019-nCoV. The modeled S proteins from the Bat-

CoV: RaTG13, CoVZC45, CoVZXC21 and LYRa3 were compared to the predicted structure of 2019nCoV S and to the template structure od SARS-CoV (Fig. 3). The amino acid homology of the modeled S proteins in comparison to the template SARS-CoV S was ~71% for all the Bat-CoV S with the exception of the LYRa3 S which shares a homology of 84.69% with the template S. Overall, all the modeled S proteins shared a similar folding pattern in comparison to SARS-CoV S and both, S1 and S2 domains showed a uniform organization (Fig. 3). As expected, differences were mostly observed at the flexible loops forming the 'head" of the S1 domain, specially at the NTD region (RBD region), were most of the amino acid variation was observed (Fig. 2A and 3). The S protein amino acid identity among the Bat-CoV (including 2019-nCoV) ranged between 75.33 – 96.65%, being the RaTG13 and the LYRa3 S proteins the ones with the highest and the lowest identity to 2019-nCoV, respectively. Despite amino acid variability, no major changes in the secondary structures and the overall folding of the proteins were observed among the modeled S structures of these viruses, suggesting a conserved organization for all the S proteins of the lineage B including the 2019-nCoV. Nevertheless, differences at the flexible loops in both domains were observed, and their impact in the 2019-nCoV S protein function must be further studied.

Structural modeling of the predicted RBM 2019-nCoV

It was recently reported that the 2019-nCoV has the potential to bind ACE2 as a receptor to infect the target cell (Hoffmann et al., 2020). This finding appears to agree with previous reports describing the ability of bat-CoVs to successfully bind and use ACE2 as a cellular receptor for infection (Ge et al., 2013; Menachery et al., 2016; Yang et al., 2015). This conservation in the

receptor usage among SARS-CoV and SARS-like bat-CoVs, contrasts with the high variability that we observed at the amino acid sequence of the RBM (Fig. 2A). Considering the high variability observed at the amino acid level of this functional region, we compared the predicted RBM structure of the 2019-nCoV and bat-CoVs to the one of SARS-CoV. Interestingly, despite the variability the modeled 2019-nCoV predicted RBM displayed a similar organization to SARS-CoV (Fig. 4 – top panel). This was also observed in the RaTG3 and LYRa3 predicted RBM structures (Fig. 4 – middle left and bottom right panels), suggesting that the RBM organization is well conserved among these viruses. In contrast, the predicted RBM of the CoVZC45 and CoVZXC21 viruses showed a different folding at this region in comparison to SARS-CoV (Fig. 4 – middle right and bottom left panels). These two last viruses showed a 5 and, a 14 amino acid deletions at the RBM sequence (Fig. 2A), which can explain the differential folding in the modeled proteins.

Structural modeling of 2019-nCoV S reveals a proteolytically-sensitive loop

Figure 2B shows a four amino acid insertion ₆₈₁PRRA₆₈₄, as well as a conserved R685 at the S1/S2 site of the 2019-nCoV. This insertion, which appears to be common among the lineage B of betacoronaviruses, suggests a differential mechanism of activation for the 2019-nCoV compared to other SARS-CoV and SARS-like Bat-CoV. At the structural level, the S1/S2 site has been shown to be difficult to solve for most CoVs structures, resulting in either incomplete structures (missing the complete S1/S2 site) or structures with an altered (*i.e.* mutated) S1/S2 site (Walls et al., 2016a; Yang et al., 2020; Yuan et al., 2017). Solving the structure of the S1/S2 site was also found to be an issue in the SARS-CoV S structure we used for our modeling analyses. We have previously shown that the S1/S2 site can be modeled in other CoV S proteins and it appears to organize as

a flexible exposed loop that extends from the S structure and suggest it could be easily accessible for proteolytic activation (Jaimes et al., 2020).

To better study the S1/S2 site structural organization, we modeled the SARS-CoV S protein based on the S structure of MHV (S1/S2 site mutated in the structure), and MERS-CoV and SARS-CoV (S1/S2 site missing in the structure) to see if the predicted structure of the S1/S2 site was similar in despite the template structure. We observed no differences in the modeled SARS-CoV S protein at the S1/S2 site, predicting an exposed flexible loop in all the three models (data not shown). Based on this, we proceeded to compare the S1/S2 site, as well as other major functional elements of the S2 domain (i.e. S2' site and fusion peptide), in the predicted structure in our SARS-CoV, 2019-nCoV and Bat-CoV S models (Fig 5). Remarkably, two features appear to exhibit distinctive characteristics in the 2019-nCoV S model: the fusion peptide, which is predicted to be organized in a more compact conformation for 2019-nCoV S than in SARS-CoV S (Fig 5 - surface models) and the region corresponding to the S1/S2 cleavage site which contains R667 in the case of SARS-CoV (Fig. 5 – S1/S2 alignment box and ribbon models). For SARS-CoV and the bat-CoV proteins, the S1/S2 site forms a short loop that appears flanking closely to the side of the trimeric structure. In the case of 2019-nCoV S, the S1/S2 site is predicted to form an extended loop that protrudes to the exterior of the trimer (Fig. 5). This feature suggests that the S1/S2 loop in 2019nCoV S could be more exposed for proteolytic processing by host cell proteases. As mentioned before, solving structure of the S1/S2 site appears to present difficulties for most of the reported CoV S structures (Fig. 6 – top panel). However, the exposed loop feature has been demonstrated in both modeled and cryo-EM CoV S structures with similar amino acid sequences at the S1/S2 site (*i.e.* FCoV and IBV, respectively) (Fig. 6 – top panel). Interestingly, FCoV viruses do not always display a S1/S2 site (Fig. 6 – top panel), which results in distinct cell entry mechanisms. We also performed an analysis of the S2' site of the 2019-nCoV in comparison to SARS-CoV and bat-CoV S proteins. As expected, differences in the modeled S2' site structure were not predicted in any of the studied spikes (Fig. 5 – S2' ribbon models). This agrees with the fact that the S2' site appears to be conserved in the studied sequences (Fig. 5 - S2' alignment box) and as we described previously, the SARS-CoV functional R797 residue at the cleavage position 1 (P1). as well as the serine at position 798 (cleavage position P1') are conserved in the 2019-nCoV and among the compared bat-CoVs. This feature also appears to be conserved in other CoVs (Fig. 6 bottom panel), however, mutations in the residues immediately upstream the SARS-CoV R797 residue (or equivalent in each virus), have been shown to result in changes in the proteolytical requirements in other CoVs (Millet and Whittaker, 2015). We observed mutations L to S and T to S, which were located upstream the P1 arginine at positions P3 and P6 in the S2' site of the 2019nCoV in comparison to SARS-CoV. These mutations were not predicted to alter the structure of the S2' in the 2019-nCoV (Fig. 5 – S2' ribbon models).

Discussion

In this study, we show the presence of a distinct insert in the S1/S2 priming loop of 2019-nCoV S, which is not shared with SARS-CoV or any SARS-related viruses. The significance of this is yet to be explored experimentally, but we consider it may fundamentally change the entry pathway of 2019-nCoV compared to other known viruses in *Betacoronavirus* lineage B. The presence of the extended S1/S2 priming loop containing paired basic residues predicts that 2019-nCoV S would

most likely be cleaved during virus assembly and delivery to the cell surface by Golgi-resident proprotein convertases such as furin. Indeed, analysis of Western blots of VSV-pseudoparticles containing 2019-nCoV S have shown the presence of cleaved S, in contrast to pseudoparticles containing SARS-CoV S (Hoffmann et al., 2020). In the case of MERS-CoV, but not SARS-CoV, it is known that priming of S by "pre-cleavage" occurs at the S1/S2 site, giving 2019-nCoV cleavage activation properties more in line with MERS-CoV than SARS-CoV (Belouzard et al., 2009; Hoffmann et al., 2020; Kleine-Weber et al., 2018; Millet and Whittaker, 2014). 2019-nCoV is currently believed to be highly SARS-CoV like with respect to its receptor binding, and the modeling studies reported here are broadly in line with this finding, despite the relatively low amino acid identity in the RBM. However it is important to remember that changes in protease usage may allow coronaviruses to undergo receptor-independent entry (virus-cell fusion) as well as affect syncytia formation (cell-cell fusion) and tissue pathology (Gallagher et al., 1992; Menachery et al., 2019; Phillips et al., 2017).

To our knowledge, the enlarged priming loop of 2019-nCov is unique among the viruses in *Betacoronavirus* lineage C. The presence of a distinct insert containing paired basic residues in the S1/S2 priming loop is common in many coronaviruses in *Betacoronavirus* lineage C (*e.g.* MERS-CoV), as well as in lineage A (*e.g.* mouse hepatitis virus, MHV) and lineage d, and is universally found in *Gammacoronavirus* S (*e.g.* IBV) (Shang et al., 2018). It is noticeably absent in most *Alphacoronaviruses*, with the clear exception of type I canine and feline coronaviruses (Jaimes et al., 2020; Millet and Whittaker, 2015). One feature of the distinct insert for of 2019-nCoV that warrants attention relates to potential changes as the virus evolves. An equivalent

loop is present in influenza HA (in this case adjacent to the fusion peptide), and insertions of basic residues into the loop are a primary marker of conversion from low pathogencity to highly pathogenic avian influenza virus (*e.g.* H5N1) (Chen et al., 1998). In coronaviruses, such loop modifications are known to affect MHV pathogenesis, and modulate neurovirulence and neuroinvasiveness of HCoV-OC43 (Frana et al., 1985; Le Coupanec et al., 2015). The FCoV is another example where S1/S2 loop modifications appear to lead directly to changes in viral pathogenesis (André et al., 2019; Jaimes et al., 2020; Licitra et al., 2013).

At present 2019-nCoV is behaving in a distinct manner compared to SARS-CoV. We believe our findings are of special importance considering that the available data suggests ACE2 as a suitable cellular receptor for 2019-nCoV entry (Huang and Herrmann, 2020; Letko and Munster, 2020). In our modeling analysis, we observed that the RBM of the 2019-nCoV predicted a similar organization as SARS-CoV and that deletions at this RBM region in other bat-CoVs are reported to not impact its ability to bind ACE2 (Ge et al., 2013; Menachery et al., 2016; Yang et al., 2015). This suggests that instead of receptor binding, the S1/S2 loop is a distinctive feature relevant to 2019-nCoV pathogenesis and marks a unique similarity to MERS-CoV. We would predict that distinct insert in 2019-nCoV S would give the virus biological properties more in line with MERS-CoV and not SARS-CoV, especially with regard to its cell entry pathway. However, it may also impact virus spread and transmission. While many epidemiological features of 2019-nCoV still need to be resolved, there are many features of transmission that align more with MERS-CoV then SARS-CoV. The reproductive number (R0) of 2019-nCoV (approx. 3-4), is higher than SARS-CoV (approx. 2-3) and while MERS-CoV has a low R0 in humans (<1), it is high in camels and in

outbreak situations (>3) (Choi et al., 2018; Dighe et al., 2019; Lipsitch et al., 2003; Liu et al., 2020; Zhou et al., 2020b). One notable feature of the S protein S1/S2 cleavage site was first observed during the purification of the MHV S protein for structural analysis (Walls et al., 2016a). MHV with an intact cleavage loop was unstable when expressed, and so we consider that the S1/S2 loop controls virus stability, likely via access to the down-stream S2' site that regulates fusion peptide exposure and activity. As such it will interesting to monitor the effects of S1/S2 loop insertions and proteolytic cleavability in the context of virus transmission, in addition to virus entry and pathogenesis.

Materials and methods:

Sequences:

Amino acid sequences of the S protein used in the phylogenetic analysis were obtained from GISAID and NCBI GenBank. GISAID accession numbers (in parenthesis) from which whole genome sequences were obtained were: 2019-nCoV-Foshan-EPI ISL 406535 (EPI ISL 406535), 2019nCoV-Foshan-EPI-ISL-406534 (EPI-ISL-406534), 2019-nCoV-France-EPI ISL 406596 (EPI ISL 406596), 2019-nCoV-Guangdong-EPI ISL 406538 (EPI ISL 406538), 2019-nCoV-Guangzhou-EPI ISL 406533 (EPI ISL 406533), 2019-nCoV-Nonthaburi-EPI ISL 403962 (EPI ISL 403962), 2019-nCoV-Shenzhen-EPI ISL 405839 (EPI ISL 405839), 2019-nCoV-Taiwan-EPI ISL 406031 (EPI ISL 406031), 2019-nCoV-USA-AZ1-ISL 406223 (EPI ISL 406223), 2019nCoV-USA-CA1-ISL 406034 (EPI ISL 406034), 2019-nCoV-USA-IL1-EPI ISL 404253 (EPI ISL 404253), 2019-nCoV-USA-WA1-EPI ISL 404895 (EPI ISL 404895), 2019-nCoV-Wuhan-WIV06-EPI ISL 402129 (EPI ISL 402129), 2019-nCoV-Zhejiang-EPI ISL 404228

(EPI ISL 404228), Bat-SL-RaTG13 (EPI ISL 402131). GenBank accession numbers (in parenthesis) from which whole genome or S gene sequences were obtained were: 2019-nCoV-Wuhan-Hu1 (MN908947.3), Bat-SL-CoVZC45 (MG772933.1), Bat-SL-CoVZXC21 (MG772934.1), Bat-SL-LYRa3 (KF569997.1), BatCoV/133 (DQ648794.1), BatCoV-GCCDC1 (NC 030886.1), BatCoV-HKU4-1 (EF065505.1), BatCoV-HKU5-1 (EF065509.1), BatCoV-HKU9 (NC 009021.1), BatCoV-Neo/PML-PHE1/RSA (KC869678.4), BatCoV-SC2013 (KC869678.4), Bat-CoV-BM48-31 (NC 014470.1), Bat-SL-HKU3-1 (DQ022305.2), Bat-SL-LYRa11 (KF569996.1), Bat-SL-Rf1 (DQ412042.1), Bat-SL-Rs4231 (KY417146.1), Bat-SL-Rs4255 (KY417149.1), Bat-SL-Rs4874 (KY417150.1), Bat-SL-RS672 (FJ588686.1), Bat-SL-WIV1 (KC881007.1), BtRs-BetaCoV/YN2018C BtRs-BetaCoV/YN2018D (MK211378.1), (MK211377.1), camMERS-CoV-HKFU-HKU-13 (KJ650295.1), camMERS-CoV-HKU23 (KF906251.1), camMERS-CoV-KSA-505 (KJ713295.1), camMERS-CoV-NRCE-HKU205 (KJ477102.1), camMERS-CoV-NRCE-HKU270 (KJ477103.2), CivSARS-CoV-SZ3 (P59594.1), HCoV-229E (NC 002645.1), HCoV-HKU1 (AY597011.2), HCoV-OC43 (KF963244.1), Hedgehog-CoV/VMC/DEU (KC545383.1), hMERS-CoV-EMC/2012 (JX869059.2), hMERS-CoV-England-1 (KC164505.2), hMERS-CoV-Jordan-N3 (KC776174.1), hSARS-CoV-BJ01 (AY278488.2), hSARS-CoV-GZ02 (AY390556.1), hSARS-CoV-HKU39849 (JN854286.1), hSARS-CoV-Tor2 (NC 004718.3), MHV-A59 (M18379.1).

For S protein modeling, amino acid sequences of SARS-CoV Urbani (AAP13441.1), 2019-nCoV-Wuhan-Hu1 (MN908947.3), , Bat-SL-CoVZC45 (MG772933.1), Bat-SL-CoVZXC21 (MG772934.1), Bat-SL-LYRa3 (KF569997.1) and FCoV WSU-79-1683 (JN634064.1) were obtained from the NCBI

GenBank, and Bat-SL-RaTG13 (EPI_ISL_402131) was obtained from GISAID data base. Amino acid sequence of the FCoV-TN406 S was provided by Prof. Susan Baker (Loyola University Chicago).

Amino acid alignments and phylogenetic trees:

Sequences alignments were performed on coronavirus S protein sequences using MAFFT v7.388 (Katoh et al., 2002; Katoh and Standley, 2013). A Maximum-Likelihood phylogenetic tree based on the S protein alignment was generated using PhyML (Guindon et al., 2010). Numbers at nodes indicate bootstrap support (100 bootstraps). Sequence alignment display and formatting was performed using Geneious R10 (Biomatters) and phylogenetic tree display and formatting was performed using FigTree 1.4.3 (http://tree.bio.ed.ac.uk/).

S protein modeling:

Beta-CoV S protein structures and amino acid sequences were obtained from the RCSB Protein Data Base: HCoV-HKU1 (PDB# 5I08), MHV (PDB# 3JCL), MERS-CoV (PDB# 6Q05), SARS-CoV (PDB# 5X58), FCoV-UU4 (PDB# 6JX7), IBV-M41 (PDB# 6CV0) and HCoV-NL63 (PDB# 5SZS). Pairwise amino acid alignments between each of the Beta-CoV and the 2019-nCoV were performed using Geneious Prime® (v.2019.2.3. Biomatters Ltd.) and exported as *.FASTA file extension for further application. S protein models were built using UCSF Chimera (v.1.14, University of California) through modeler homology tool of the Modeller extension (v.9.23, University of California) and edited using PyMOL (v.2.0.7, Schrodinger LLC.). 2019-nCoV S models built was based on HCoV-HKU1, MHV, MERS-CoV and SARS-CoV S structures. Models for the Bat-CoV RaTG13, Bat-CoV CoVZC45, Bat-CoV CoVZXC21, Bat-CoV LYRa3 and SARS-CoV were built based on SARS-CoV S structure. Finally, FCoV-TN406 and FCoV WSU-78-1683 S models were built based on HCoV-NL63 S structure. Additional SARS-CoV S models based on MHV and MERS-CoV S structures were built to validate our modeling approach (data not shown).

Acknowledgements

We thank all member of the Whittaker and Daniel labs at Cornell University for comments and

discussion, and Joshua Chappie for invaluable help with structural modeling. Work in the author's

laboratory is supported by the National Institutes of Health (research grant R01AI35270).

References

- 1. André, N.M., Cossic, B., Davies, E., Miller, A.D., and Whittaker, G.R. (2019). Distinct mutation in the feline coronavirus spike protein cleavage activation site in a cat with feline infectious peritonitis-associated meningoencephalomyelitis. Journal of Feline Medicine and Surgery Open Reports *5*, 2055116919856103.
- 2. Belouzard, S., Chu, V.C., and Whittaker, G.R. (2009). Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences *106*, 5871-5876.
- 3. Belouzard, S., Millet, J.K., Licitra, B.N., and Whittaker, G.R. (2012). Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses *4*, 1011-1033.
- Chan, J.F., Yuan, S., Kok, K.H., To, K.K., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C.C., Poon, R.W., et al. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. pii: S0140-6736(20)30154-9.
- 5. Chen, J., Lee, K.H., Steinhauer, D.A., Stevens, D.J., Skehel, J.J., and Wiley, D.C. (1998). Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell *95*, 409-417.
- 6. Choi, S., Jung, E., Choi, B.Y., Hur, Y.J., and Ki, M. (2018). High reproduction number of Middle East respiratory syndrome coronavirus in nosocomial outbreaks: mathematical modelling in Saudi Arabia and South Korea. J Hosp Infect *99*, 162-168.
- 7. Cui, J., Li, F., and Shi, Z.L. (2019). Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol *17*, 181-192.
- 8. Dighe, A., Jombart, T., van Kerkhove, M., and Ferguson, N. (2019). A mathematical model of the transmission of middle East respiratory syndrome coronavirus in dromedary camels (*Camelus dromedarius*). International Journal of Infectious Diseases *79*, 1.

- 9. Frana, M.F., Behnke, J.N., Sturman, L.S., and Holmes, K.V. (1985). Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: host-dependent differences in proteolytic cleavage and cell fusion. J Virol *56*, 912-920.
- 10. Gallagher, T.M., Buchmeier, M.J., and Perlman, S. (1992). Cell receptor-independent infection by a neurotropic murine coronavirus. Virology *191*, 517-522.
- Ge, X.Y., Li, J.L., Yang, X.L., Chmura, A.A., Zhu, G., Epstein, J.H., Mazet, J.K., Hu, B., Zhang, W., Peng, C., et al. (2013). Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535-538.
- 12. Gralinski, L.E., and Menachery, V.D. (2020). Return of the Coronavirus: 2019-nCoV. Viruses 12.
- 13. Guindon, S., Dufayard, J.F., Lefort, V., Anisimova, M., Hordijk, W., and Gascuel, O. (2010). New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol *59*, 307-321.
- 14. Heald-Sargent, T., and Gallagher, T. (2012). Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses *4*, 557-580.
- 15. Hoffmann, M., Kleine-Weber, H., Krüger, N., Müller, M., Drosten, C., and Pöhlmann, S. (2020). The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv, 2020.2001.2031.929042.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
- 17. Huang, Q., and Herrmann, A. (2020). Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV). bioRxiv, 2020.2002.2001.930537.
- 18. Hulswit, R.J., de Haan, C.A., and Bosch, B.J. (2016). Coronavirus Spike Protein and Tropism Changes. Adv Virus Res *96*, 29-57.
- 19. Huynh, J., Li, S., Yount, B., Smith, A., Sturges, L., Olsen, J.C., Nagel, J., Johnson, J.B., Agnihothram, S., Gates, J.E., *et al.* (2012). Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol *86*, 12816-12825.
- 20. International Committee on Taxonomy of Viruses, ICTV. (2018). Virus Taxonomy: 2018b Release. URL: <u>https://talk.ictvonline.org/taxonomy/</u>. Revised on: February 9th, 2020.
- 21. Jaimes, J.A., Millet, J.K., Stout, A.E., Andre, N.M., and Whittaker, G.R. (2020). A Tale of Two Viruses: The Distinct Spike Glycoproteins of Feline Coronaviruses. Viruses *12*. pii: E83
- 22. Jaimes, J.A., and Whittaker, G.R. (2018). Feline coronavirus: Insights into viral pathogenesis based on the spike protein structure and function. Virology *517*, 108-121.
- 23. Johns Hopkins University, Center for Systems Science and Engineering. (2020). Coronavirus 2019-nCoV Global Cases. URL: <u>https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40</u> <u>299423467b48e9ecf6</u>. Revised: February 9th, 2020.
- 24. Katoh, K., Misawa, K., Kuma, K., and Miyata, T. (2002). MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res *30*, 3059-3066.
- 25. Katoh, K., and Standley, D.M. (2013). MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol *30*, 772-780.

- 26. Kirchdoerfer, R.N., Cottrell, C.A., Wang, N., Pallesen, J., Yassine, H.M., Turner, H.L., Corbett, K.S., Graham, B.S., McLellan, J.S., and Ward, A.B. (2016). Pre-fusion structure of a human coronavirus spike protein. Nature *531*, 118-121.
- 27. Kleine-Weber, H., Elzayat, M.T., Hoffmann, M., and Pohlmann, S. (2018). Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Sci Rep *8*, 16597.
- 28. Lai, A.L., Millet, J.K., Daniel, S., Freed, J.H., and Whittaker, G.R. (2017). The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent Manner. Journal of molecular biology. *429*. 3875-3892.
- 29. Le Coupanec, A., Desforges, M., Meessen-Pinard, M., Dube, M., Day, R., Seidah, N.G., and Talbot, P.J. (2015). Cleavage of a Neuroinvasive Human Respiratory Virus Spike Glycoprotein by Proprotein Convertases Modulates Neurovirulence and Virus Spread within the Central Nervous System. PLoS Pathog *11*, e1005261.
- 30. Letko, M., and Munster, V. (2020). Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. bioRxiv, 2020.2001.2022.915660.
- 31. Li, F., Li, W., Farzan, M., and Harrison, S.C. (2005). Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (New York, NY) *309*, 1864-1868.
- 32. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau, E.H.Y., Wong, J.Y., et al. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine. doi: 10.1056/NEJMoa2001316.
- 33. Licitra, B.N., Millet, J.K., Regan, A.D., Hamilton, B.S., Rinaldi, V.D., Duhamel, G.E., and Whittaker, G.R. (2013). Mutation in spike protein cleavage site and pathogenesis of feline coronavirus. Emerg Infect Dis *19*, 1066-1073.
- Lipsitch, M., Cohen, T., Cooper, B., Robins, J.M., Ma, S., James, L., Gopalakrishna, G., Chew, S.K., Tan, C.C., Samore, M.H., *et al.* (2003). Transmission dynamics and control of severe acute respiratory syndrome. Science (New York, NY) *300*, 1966-1970.
- 35. Liu, T., Hu, J., Kang, M., Lin, L., Zhong, H., Xiao, J., He, G., Song, T., Huang, Q., Rong, Z., *et al.* (2020). Transmission dynamics of 2019 novel coronavirus (2019-nCoV). bioRxiv, 2020.2001.2025.919787.
- 36. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., *et al.* (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. pii: S0140-6736(20)30251-8.
- 37. Madu, I.G., Roth, S.L., Belouzard, S., and Whittaker, G.R. (2009). Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J Virol *83*, 7411-7421.
- Menachery, V.D., Dinnon, K.H., 3rd, Yount, B.L., Jr., McAnarney, E.T., Gralinski, L.E., Hale, A., Graham, R.L., Scobey, T., Anthony, S.J., Wang, L., *et al.* (2019). Trypsin treatment unlocks barrier for zoonotic bat coronaviruses infection. J Virol. pii: JVI.01774-19.
- 39. Menachery, V.D., Graham, R.L., and Baric, R.S. (2017). Jumping species-a mechanism for coronavirus persistence and survival. Curr Opin Virol 23, 1-7.
- 40. Menachery, V.D., Yount, B.L., Jr., Sims, A.C., Debbink, K., Agnihothram, S.S., Gralinski, L.E., Graham, R.L., Scobey, T., Plante, J.A., Royal, S.R., *et al.* (2016). SARS-like WIV1-CoV poised

for human emergence. Proceedings of the National Academy of Sciences of the United States of America *113*, 3048-3053.

- 41. Millet, J.K., and Whittaker, G.R. (2014). Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proceedings of the National Academy of Sciences of the United States of America *111*, 15214-15219.
- 42. Millet, J.K., and Whittaker, G.R. (2015). Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis. Virus Research *202*, 120-134.
- 43. Perlman, S. (2020). Another Decade, Another Coronavirus. New England Journal of Medicine. doi: 10.1056/NEJMe2001126. doi: 10.1056/NEJMc2001272.
- 44. Phan, L.T., Nguyen, T.V., Luong, Q.C., Nguyen, T.V., Nguyen, H.T., Le, H.Q., Nguyen, T.T., Cao, T.M., and Pham, Q.D. (2020). Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. New England Journal of Medicine.
- 45. Phillips, J.M., Gallagher, T., and Weiss, S.R. (2017). Neurovirulent Murine Coronavirus JHM.SD Uses Cellular Zinc Metalloproteases for Virus Entry and Cell-Cell Fusion. J Virol *91*.
- 46. Seidah, N.G. (2011). The proprotein convertases, 20 years later. Methods Mol Biol *768*, 23-57.
- 47. Seidah, N.G., Sadr, M.S., Chretien, M., and Mbikay, M. (2013). The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. The Journal of Biological Chemistry *288*, 21473-21481.
- 48. Shang, J., Zheng, Y., Yang, Y., Liu, C., Geng, Q., Luo, C., Zhang, W., and Li, F. (2018). Cryo-EM structure of infectious bronchitis coronavirus spike protein reveals structural and functional evolution of coronavirus spike proteins. PLoS Pathog *14*, e1007009.
- Shang, J., Zheng, Y., Yang, Y., Liu, C., Geng, Q., Tai, W., Du, L., Zhou, Y., Zhang, W., and Li, F. (2017). Cryo-EM structure of porcine delta coronavirus spike protein in the pre-fusion state. J Virol. *92*. pii: e01556-17.
- 50. Walls, A.C., Tortorici, M.A., Bosch, B.J., Frenz, B., Rottier, P.J., DiMaio, F., Rey, F.A., and Veesler, D. (2016a). Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature *531*, 114-117.
- Walls, A.C., Tortorici, M.A., Frenz, B., Snijder, J., Li, W., Rey, F.A., DiMaio, F., Bosch, B.J., and Veesler, D. (2016b). Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nature Structural & Molecular Biology 23, 899-905.
- 52. Wan, Y., Shang, J., Graham, R., Baric, R.S., and Li, F. (2020). Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. pii: JVI.00127-20.
- 53. Woo, P.C., Lau, S.K., Lam, C.S., Lau, C.C., Tsang, A.K., Lau, J.H., Bai, R., Teng, J.L., Tsang, C.C., Wang, M., et al. (2012). Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 86, 3995-4008.
- 54. World Health Organization, WHO. (2004). Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. URL:

https://www.who.int/csr/sars/country/table2004_04_21/en/. Revised on: February 9th, 2020.

- World Health Organization, WHO. (2019). Middle East respiratory syndrome coronavirus (MERS-CoV). URL: <u>https://www.who.int/emergencies/mers-cov/en/</u>. Revised on: February 9th, 2020.
- 56. Wu, J.T., Leung, K., and Leung, G.M. (2020). Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. pii: S0140-6736(20)30260-9.
- 57. Xu, L., Zhang, Y., Liu, Y., Chen, Z., Deng, H., Ma, Z., Wang, H., Hu, Z., and Deng, F. (2009). Angiotensin-converting enzyme 2 (ACE2) from raccoon dog can serve as an efficient receptor for the spike protein of severe acute respiratory syndrome coronavirus. J Gen Virol *90*, 2695-2703.
- 58. Yang, T.J., Chang, Y.C., Ko, T.P., Draczkowski, P., Chien, Y.C., Chang, Y.C., Wu, K.P., Khoo, K.H., Chang, H.W., and Hsu, S.D. (2020). Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans. Proceedings of the National Academy of Sciences of the United States of America *117*, 1438-1446.
- 59. Yang, X.L., Hu, B., Wang, B., Wang, M.N., Zhang, Q., Zhang, W., Wu, L.J., Ge, X.Y., Zhang, Y.Z., Daszak, P., *et al.* (2015). Isolation and Characterization of a Novel Bat Coronavirus Closely Related to the Direct Progenitor of Severe Acute Respiratory Syndrome Coronavirus. J Virol *90*, 3253-3256.
- 60. Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi, Y., *et al.* (2017). Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nature Communications *8*, 15092.
- 61. Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., *et al.* (2020a). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. doi: 10.1038/s41586-020-2012-7.
- 62. Zhou, T., Liu, Q., Yang, Z., Liao, J., Yang, K., Lü, X., and Zhang, W. (2020b). Preliminary prediction of the basic reproduction number of the Wuhan novel coronavirus 2019-nCoV. arXiv preprint arXiv:200110530.
- 63. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., *et al.* (2020). A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. doi: 10.1056/NEJMoa2001017.




Figure 1. Comparative analyses of 2019-nCoV S protein sequence. A. Protein sequence identities between 2019-nCoV S with SARS-CoV S. The S protein sequences were aligned and the sequence identities obtained for the full-length and domains/subdomains are shown on the S protein diagram. Amino acid delineations of domains and subdomains are based on the SARS-CoV S protein. **B.** Phylogenetic analysis of 2019-nCoV S protein. The S protein sequence of 15 isolates of 2019-nCoV were aligned with representatives of all four *Betacoronavirus* lineages. A Maximum-Likelihood tree was generated based on the alignment. The tree was rooted using the alphacoronavirus HCoV-229E S sequence. Number at nodes indicate bootstrap support (100 replicates). Accession numbers of sequences used in the analyses are found in the methods section.

A

SARS-CoV					357	367	377			
019-nCoV	331	340			370					420
at-SL-RaTG13	331	340	350		370					420
at-SL-CoVZC45		336					386			416
oat-SL-CoVZXC21		335			365	375	385			415
pat-SL-LYRa3	322					371				411
at se entas										
	417	427	437	447	RBN 457	467	476	486	496	
SARS-CoV									OPVRVVVISE	ELLNAPAT
2019-nCoV		NNLDSKV(GGNYNYLYRI	FRKSNLKPF		AGSTPCNGVI	GENCY PLQS	GEQPTN GNGN		ELLHAPATN
oat-SL-RaTG13			GGNENYLYRI	FRKANKPF	RDISTELYQ	AG <mark>SKPĊN</mark> GQT	GLNCYYPLYF	RYGEYPTD GNGH		ELLNAPAT
bat-SL-CoVZC45		AKQDVG -	<mark>NYFYR</mark> S	HRSTKLKPF				TYDEN PNY PLEY 476		ELLNAPATN
oat-SL-CoVZXC21				HRSTKERPE	RDLSSD	471		TYDEN PNPLEY		ELLNAPAT
bat-SL-LYRa3	MGCVLAWNT		SGNEHYKYRS	LRHGKLRPF		PDGKPĊT-PF		YGFYTTNGIG	QPYR VVVLSF	ELLNAPAT
	638	647	657		51/S2		683	697		
	638	647	657		667 673		683	697		
ARS-CoV	GAEHVDTS		G A G 🛛 C A S 🛛		- R STSQKS	IVAYTMSLG	Á DISSIAYSN			
			GAG <mark>ICAS</mark> 671 GAG ICAS	HTVSLU 681 QTQTNSPRR	685 691		ÁDSSTAYSN 701 ÁENSVAYSN			
2019-nCoV			GAGECASY 671 GAGECASY 671 GAGECASY	QTQTNSPRR	685 AR 5 VASQS 687 - R SVASQS	AYTMSEG	701	NTIA P 715 NSIA P 711		
SARS-CoV 2019-nCoV bat-SL-RaTG13 bat-SL-CoVZC45	GAEHVDTS 652 GAEHVNNS 652 GAEHVNNS 679	Y C D P 661 Y C D P P 661 Y C D P P 661 Y C D P P P 661 Y C D P P P P P P P P P P P P P P P P P P	$GAG \square CASY$	QTQTNSPRR,	AR 681 SMASQS 681 687	AYTMS G	701 A <mark>E N S V</mark> A <mark>Y S N</mark> 697	NTAP 715 NSTAP 711 NSTAP 688		
2019-nCoV bat-SL-RaTG13	GAEHVDTS 652 GAEHVNNS 652 GAEHVNNS 629	Y C D P 661 Y C D P 661 Y C D P 637 Y C D P 637 Y C D P	GAGECASM GAGECASM GAGECASM GAGECASM GAGECASM GAGECASM	QTQTNSPRR, QTQTNS HTASTE	685 681 681 - R 658 5 M A S Q S 687 687 687 687 687 687 687 687 687 687	AYTMSI G AYTMSI G VAYTMSI G	701 A ENSVAYSN 697 A ENSVAYSN 674	N S A P 715 N S A P 711 N S A P 688 N S A P 687		
2019-nCoV bat-SL-RaTG13 bat-SL-CoVZC45	G A H M N S 652 G A H M N N S 652 G A H M N N S 679 G A H M N A S 678	YECDUP 661 YECDUP 638 YECDUP 637 YECDUP 651	GAGCASM GAGCASM GAGCASM GAGCASM GAGCASM 647	681 QTQTNSPRR, QTQTNS HTASTE HTASTE	685 691 687 SMASQS 681 SMASQS 683 687 684 687 685 664 658 664 658 664 658 664 657 663	AYTMS G AYTMS G VAYTMS G VAYTMS G	701 A A N S N A Y S N 697 A A N S N A Y S N 674 A N S A Y A N 673	N T A P 715 N S A P 711 N S A A P 687 N S A P 687 N S A P 701		
2019-nCoV pat-SL-RaTG13 pat-SL-CoVZC45 pat-SL-CoVZXC21	G A H M N S 652 G A H M N N S 652 G A H M N N S 679 G A H M N A S 678 G A H M N A S 678 G A H M N A S 674	YECDUP 661 YECDUP 638 YECDUP 637 YECDUP 651	$[G A G] = \begin{pmatrix} c \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 641 \\ $	681 QTQTNSPRR, QTQTNS HTASTE HTASTE	687 687 687 687 687 687 658 658 658 657 657 657 663 664 664 664 664 664 664 664	AYTMS G AYTMS G VAYTMS G VAYTMS G	701 A C N S M A Y S N 697 A C N S M A Y S N 674 A C N S M A Y A N 673 A C N S A A A A N 673 673 A C N S A A A A N	N T A P 715 N S A P 711 N S A A P 687 N S A P 687 N S A P 701		
2019-nCoV pat-SL-RaTG13 pat-SL-CoVZC45 pat-SL-CoVZXC21	G A H M N S 652 G A H M N N S 652 G A H M N N S 679 G A H M N A S 678 G A H M N A S 678 G A H M N A S 674	YECDUP 661 YECDUP 638 YECDUP 637 YECDUP 651	$[G A G] = \begin{pmatrix} c \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 641 \\ $	681 QTQTNSPRR, QTQTNS HTASTE HTASTE	687 687 687 687 687 687 658 658 658 657 657 657 663 664 664 664 664 664 664 664	AYTMS G AYTMS G VAYTMS G VAYTMS G	701 A C N S M A Y S N 697 A C N S M A Y S N 674 A C N S M A Y A N 673 A C N S A A A A N 673 673 A C N S A A A A N	N T A P 715 N S A P 711 N S A A P 687 N S A P 687 N S A P 701		
2019-nCoV oat-SL-RaTG13 oat-SL-CoVZC45 oat-SL-CoVZXC21 oat-SL-LYRa3	G A H M N S 652 G A H M N N S 652 G A H M N N S 679 G A H M N A S 678 G A H M N A S 678 G A H M N A S 642	YECDUP 661 YECDUP 638 YECDUP 637 YECDUP 651	$[G A G] = \begin{pmatrix} c \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 641 \\ $	681 QTQTNSPRR, QTQTNS HTASTE HTASTE	687 687 687 687 687 687 658 658 658 657 657 657 663 664 664 664 664 664 664 664	AYTMS G AYTMS G VAYTMS G VAYTMS G	701 A C N S M A Y S N 697 A C N S M A Y S N 674 A C N S M A Y A N 673 A C N S A A A A N 673 673 A C N S A A A A N	N T A P 715 N S A P 711 N S A A P 687 N S A P 687 N S A P 701		
2019-nCoV oat-SL-RaTG13 oat-SL-CoVZC45 oat-SL-CoVZXC21 oat-SL-LYRa3	G A H M N S 652 G A H M N N S 652 G A H M N N S 679 G A H M N A S 678 G A H M N A S 678 G A H M N A S 642	YECDUP 661 YECDUP 638 YECDUP 637 YECDUP 651	$[G A G] = \begin{pmatrix} c \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 671 \\ 641 \\ $	931 QTQTNS HTASING HTASING HTASING	687 687 687 687 687 687 658 658 658 657 657 657 663 664 664 664 664 664 664 664	A M TMS II G A M TMS II G II A M TMS II G III A M TMS II G III A M TMS II G	701 A C N S M A Y S N 697 A C N S M A Y S N 674 A C N S M A Y A N 673 A C N S A A A A N 673 673 A C N S A A A A N	N T A P 715 N S A P 711 N S A A P 687 N S A P 687 N S A P 701		
2019-nCoV Dat-SL-RaTG13 Dat-SL-CoVZC45 Dat-SL-CoVZXC21 Dat-SL-LYRa3	G A BH MDT S G A BH MN N S G A BH MN N S G A BH MN N S G A BH MN A S G A BH MN A S G A BH MN A S		IGA GILČA SM IGA GILČA SM GA GILČA SM GA GILČA SM IGA GILČA SM IGA GILČA SM	CTQTNSPRR. QTQTNS HTASIM HTASIM HTASIM S2'	645 641 641 647 647 647 647 647 647 647 647	A MITMS C		NT A P 775 NS A P 771 NS A P 688 NS A P 791 NS A P 791 NS A P		
2019-nCoV Dat-SL-RaTG13 Dat-SL-CoVZC45 Dat-SL-CoVZXC21 Dat-SL-LYRa3	G A BH MD T SI G A BH MN N SI G A BH MN N SI G A BH MN A SI			QTQTNSPRR, QTQTNSPRR, QTQTNSPRR, HTASIMI HTASIMI HTASIMI State Y Y Y Y Y	645 641 641 SMAS Q 451 641 647 643 647 644 647 645 644 647 SMAS Q 451 648 644 647 644 648 644 649 644 644 644 645 644 644 644		201 507 507 507 507 507 507 507 507	NT A P 715 NS A P 711 NS A P 658 NS A P 701 NS A P 701 NS A P 701 NS A P		
2019-nCoV Dat-SL-RaTG13 Dat-SL-CoVZC45 Dat-SL-CoVZXC21 Dat-SL-LYRa3	G A BH MD T S G A BH MN N S G A BH MN N S G A BH MN A S G		IG A G C A SM IG A G	QTQTNSPRR. QTQTNSPRR. QTQTNS HTASID HTASID HTASID S22' Y PIKPTKR 797 PIKPTKR 815	645 647 647 647 647 647 647 647 647	A MITMS I G A MITMS I G I A MIA G I I A MAG I M	701 697 697 697 607 607 607 607 607 607 607 60	NITAP P 775 775 NSTAP P		
2019-nCoV Dat-SL-RaTG13 Dat-SL-CoVZC45 Dat-SL-CoVZXC21 Dat-SL-LYRa3 C SARS-CoV 2019-nCoV Dat-SL-RaTG13	G A BH MD T SI G A BH MN N SI G A BH MN N SI G A BH MN A SI C MMK T P PI 72 KOMK T P PI 72	777 777 777 777 777 777 777 777 78 6 79 6 79 6 78 6 78 6 78 6 78 6 78 6 78 6 78 6 78 6 78 6 78 6 78 6 78 6 79 6 79 6 79 6 79 6 79 6 79 6 6 6	IG A G C A SM IN S Q B05 PINE S Q PIN IN S Q PIN IN S Q PIN IN S Q PIN	QTQTNSPRR, QTQTNSPRR, QTQTNS HTASID HTASID HTASID S22' Y PIKPTKR 797 PIKPTKR 815 PSKPSKR 815 S	665 671 673 MAS Q QS 674 SMAS Q QS 675 SMAS Q QS 678 SMAS Q QS 678 SMAS Q QS 678 SMAS Q QS 678 SMAS Q QS 679 STAS QS 670 STAS QS 671 N TG Q KS 671 N TG Q KS 672 STAS QS 673 STAS QS 674 STAS QS 675 STAS QS 676 STAS QS 677 N TG Q KS 678 STAS QS 679 STAS QS 670 STAS QS 671 STAS QS 673 STAS QS 674 STAS QS 675 STAS QS 676 STAS QS 677 STAS QS 678 STAS QS 679 STAS QS 670 STAS QS 671 STAS QS		817 K	NITAP P 775 775 NSTAP P		
2019-nCoV bat-SL-RaTG13 bat-SL-CoVZC45 bat-SL-CoVZXC21	G A BH MDT S G A BH MN N S G A BH MN N S G A BH MN N S G A BH MN A S G A	777 777 777 777 777 777 777 777 777 777 777 777 777 777 777 777 777 777 777 777 777 791 777 791 7791 6 7761 6		QTQTNSPRR, QTQTNSPRR, QTQTNS HTASIII HTASIII HTASIII S22' Y PIKPSKRSS PSKPSKRSS PSKPSKRSS PSKPSKRSS	665 667 685 687 687 SMAS Q 627 687 STA 620 687 STA 620		\$17 \$10 <td>N T A P 715 715 717 N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P A A B S S A B S S A B<!--</td--><td></td><td></td></td>	N T A P 715 715 717 N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P N S A P A A B S S A B S S A B </td <td></td> <td></td>		

Figure 2. Sequence alignments of S protein regions of 2019-nCoV with closely related species. S protein sequences from 2019-nCoV, SARS-CoV, and closely related bat coronaviruses, bat-SL-RaTG13, bat-SL-CoVZC45, bat-SL-CoVZXC21, bat-SL-LYRa3 were aligned. The regions corresponding to the receptor binding domain (RBD, A.), the S1/S2 cleavage site (red arrow, **B.**) and S2' cleavage site (red arrow, **C.**) are shown. RBM: receptor binding motif. Accession numbers of sequences used in the analyses are found in the methods section.





Figure 3. 2019-nCoV and bat-CoVs S protein models. The modeled S protein of 2019-nCoV, RaTG13, CoVZC45, CoVCZXC21 and LYRa3 are compared to SARS-CoV S structure. The amino acid homology between the modeled proteins and SARS-CoV S is noted in red and amino acid differences in blue in both models and identity scale. The S amino acid identity between 2019-nCoV and bat-CoVs is also noted (black identity scale).






Figure 4. 2019-nCoV and bat-CoVs modeled RBM. Surface view of SARS-CoV S structure and 2019-nCoV, RaTG13, CoVZC45, CoVCZXC21 and LYRa3 S models. SARS-CoV RBM (red) and flanking residues (yellow) are noted. RBM in the modeled structures is also noted according to their amino acid homology (red) and differences (blue) to SARS-CoV.




Figure 5. 2019-nCoV S1//S2 and S2' activation sites. The S1/S2 and S2' activation sites of SARS-CoV and 2019-nCoV S models are shown in surface and ribbon views. S1/S2 and S2' sites of bat-CoVs are shown in ribbon view. Amino acid homology to SARS-CoV is noted as follows: S1/S2 site: homology (red) and differences (blue); S2' site: homology (yellow) and differences (magenta). Amino acid alignments of the S1/S2 and S2' sites are shown, and homology is also noted.




Figure 6. CoVs S1/S2 and S2' site. The S1/S2 and S2' activation sites of FCoV, MERS-CoV and IBV. S models are shown ribbon views. Amino acid homology to SARS-CoV is noted as follows: S1/S2 site: homology (red) and differences (blue); S2' site: homology (yellow) and differences (magenta). Amino acid sequences of the S1/S2 and S2' sites are shown.

	1	10	20	30	40	50	60
SARS-CoV 2019-nCoV	METELLEL MEVELVLL 70				MRGVYYPDE TRGVYYPDKV 110	FRSDTLYLTQ FRSSVLHSTQ 120	
SARS-CoV 2019-nCoV	VTGEHTIN	<u>-</u> HT	FGNPVIPĖK	GIYFAATĖK		STMNNKSQSV	
SARS-CoV 2019-nCoV				160 TQTHTMIEDN MESEFRVYSS			190 SGNEKHLRE OGNEKNLRE
SARS-CoV		210	220	230		250	260 AFSP AQD
2019-nCoV	FVFKNIDG	Y F K I Y S K H T 270	P N L V R D L P C 280	Q G F S A L E P L V 290		FQTLLALHRS 310	YLTPGDSSS 320
SARS-CoV 2019-nCoV	GWTAGAAA	Y Y <mark>V</mark> G Y L <mark>Q P R</mark>	TFLLKYN <mark>E</mark> N(GTTTDAVDCA		IKSFTVEKGI	YQTSNERVV YQTSNERVQ
SARS-CoV 2019-nCoV	PSGDVVRF PTESIVRF	PNITNLCPF	GEVENATREA	A <mark>S V Y</mark> A WNRKR	I S N C V A D Y S V		KCYGVSPTK
SARS-CoV 2019-nCoV						440 VLAWNTRNID VLAWNSNNLD	
SARS-CoV	460	470	480	490	500		520
2019-nCoV	LYRLFRK <mark>S</mark>	NLKPFERDI 530	STELYQAGS 540	FPCNGVEGFN 550	CYFPLQSYGF 560	Q P T N G V G Y Q P 570	YRVVVLSFE 580
SARS-CoV 2019-nCoV	LLNAPATV LLHAPATV 590					QQEGRDVSDF QQEGRDIADT 640	TDSVRDPKT TDAVRDPQT 650
SARS-CoV 2019-nCoV	SEILDISP	<mark>C A F</mark> G G <mark>V S</mark> V I C S F G G <mark>V S</mark> V I	T P G <mark>T N A S S E N</mark> T P G <mark>T N T S N Q N</mark>	VAVLYQDVNC VAVLYQDVNC	T DVST ATHÅD TEVPVATHAD	QLTPAWRIYS QLTPTWRVYS	TGNNVFQTQ TGSNVFQTR
SARS-CoV 2019-nCoV					690 LLRSTSQKSI RARSVASQSI	700 VAYTMSLGAD AYTMSLGAE	
SARS-CoV 2019-nCoV				750 CNMYLCGDST CTMYLCGDST		5FCTQLNRAL SFCTQLNRAL	
SARS-CoV		790	800		820		840
2019-nCoV	NTQEVFAQ 850	VKQIYKTPP 860	KDFGGFNF ⁸⁷⁰	S Q I L P D P S K P 880	SKRSFIEDLL 890	FNKVTLADA G 900	FIKQYGDCL 910
SARS-CoV 2019-nCoV	G <mark>DINARDL</mark> GDIAARDL	I C A Q K F N G L	TVLPPLLTD	MAQYTSAL	LAGTITSGWT	EGAGAALQIP EGAGAALQIP	FAMQMAYRF
SARS-CoV 2019-nCoV					950 TALGKLQDVV SALGKLQDVV	960 NQNAQALNTL	970 VKQLSSNFG VKQLSSNFG
SARS-CoV		990	1,000	1,010 TGRLQSLQTY	1,020	1,030	1,040
2019-nCoV		1,050	1,060	1,070	1,080	1,090	KMSECVLGQ 1,100
SARS-CoV 2019-nCoV	SKRVDFCG SKRVDFCG 1,110	K G Y H L M S F P K G Y H L M S F P 1,120	QAAPHGVVFI QSAPHGVVFI 1,130	HVTYVPSQE HVTYVPAQE 1,140	RNETTAPALC KNETTAPALC 1,150	HEGKAYEPRE HDGKAHEPRE 1,160	GVFVFNGTS GVFVSNGTH 1,170
SARS-CoV 2019-nCoV	WEITQRNE	FSPQIITTD		V V I G I I NNTV	YDPLQPELDS		NHTSPDVDL
SARS-CoV	G <mark>DIS</mark> G <mark>IN</mark> A	1,180 <mark>S V V N I Q K E I</mark>	1,190 DRLNEVAKNI	1,200 NESLIDLQE	1,210 GKYEQYIKW	1,220 PWYVWLGFIA	1,230 GLIAIVMVT
2019-nCoV	1,240	1,250		1,270	1,277	(PWYIWLGFIA	GLIAIVMVT
SARS-CoV 2019-nCoV		CCSCLKGCC	SCGSCCKFD SCGSCCKFD	DDSEPVLKG DDSEPVLKG			

Supplementary figure 1. Sequence alignment of the S protein of 2019-nCoV with SARS-CoV. The sequences of the S proteins of 2019-nCoV and SARS-CoV were aligned and the full-length alignment is shown. Accession numbers of sequences used in the analysis are found in the methods section.

Supplementary	figure	2.	Sequence	alignment	of	the	S1/S2	region	of	2019-nCoV	with	
---------------	--------	----	----------	-----------	----	-----	-------	--------	----	-----------	------	--

Sup	hie	mentary figure					region		110
		HCoV-HKU1	NADNETDYSMSSCAL			SASYREVTE		SILE SMG GLYELKUP	ĺ
	Α	MHV-A59		RMGAGLCVDY			PYTPMLVND	SMQSVDGLYEMQTP	2
	A	camCoV-HKU23							5
		HCoV-OC43				65 7	75	785 79 SEPNGG XELOUP	8
		100-0045	701 709	719	5 REAL STRUCT	34	744	752 76	4
		Hedgehog-CoV/VMC/DEU	GERN-TSDTMEDCT	PEGQSECAKP		NNTEALVHM-		S - VUNSTEFQVSUP	į.
		BatCoV-Neo/PML-PHE1/RSA	GEHE - TND TWEECH		PNTNLRSG-	- <mark>R S T E</mark> G E G S E -	- AYNS - PLRV		i .
		camMERS-CoV-NRCE-HKU205	GLVN - SSLFVEDCKI	PLGQSLCALPDT		P G Q M R L A SIL -			3
		camMERS-CoV-NRCE-HKU270	716 724 GLVN - SSLFVEDCKI	PLGQSLCALPDT	744 7			771 78 771 78 78 78 78 78 78 78 78 78 78	3
		hMERS-CoV-lordan-N3	716 724 GLVN - SSLFVEDCKI		744 7		763		3
		camMERS-CoV-HKFU-HKU-13	716 724		744 7				3
	0		GLVN - SSLFVEDCK	734	744 7	53	763	771 78	3
	C	camMERS-CoV-KSA-505	GLVN - SSLFVEDCKI	PLGQSLCALPDT 734	744 7	PGEMRLASII -	- AENH - PIQV	D - QUNSSYFKLSTP 771 78	3
		hMERS-CoV-EMC/2012	GLVN - SSLFVEDCKI	PLGQSLCALPDT	PSTLTPRSVRS- 744 7		- AENH - PIQV	P - QUNSSYFKLSIP 771 78	3
		hMERS-CoV-England-1	GLVN - SSLFVEDCKI	P G G S C A L P D T	PSTLTPRSVRS-		- AENH - PEQV	D - QLNSSYFKLSTP 770	2
		BatCoV-HKU4-1					- NYTS - PIVV		2
		BatCoV/133	GUSN-NSLVVSDCKI					T-PINSSGETAA	į.
		BatCoV-HKU5-1	GEIN-SSMVVDECQL		111			A - PINSTGFVVAVP	í.
		BatCoV-SC2013	687 GLVN-SSLIVDDCRI			PQPMQLATE-		738 N - PLNSSGFVVEIP	5
			641 650	658	664	671	680 - AYTM - SE GD	688 70	1
		Bat-SL-BM48-31	642 651	P G A G C A K Y	TNMSSTL	671	680	688 70	1
		Bat-SL-LYRa11		PIGAGICASM	HTASLE	- RNTDQKSLV-	- AMTM - SE GA		1
		Bat-SL-LYRa3		P G A G C A S M		- RNTGQKSTV-	- AYTM - SE GA		8
		Bat-SL-WIV1	GAEHVOTSY ECD	PIGAGICASY		- RSTSQKSIV	ANTM - SEGA		į.
		Bat-SL-Rs4874	GAEHVDTSY ECD	P GAG CASY	HTVSSE	- RSTSQKSTV-	ATM-SEGA		í .
		hSARS-CoV-GZ02		655 P G A G C A S Y			676 - AMTM - SE GA	69 DSSIAYSNNTAP	7
		hSARS-CoV-BJ01	638 647				676 - AYTM - SLGA		7
		hSARS-CoV-Tor2	638 647					684 69	7
			638 647	655	661	667	676	684 69	7
0		CivSARS-CoV-SZ3	638 647	P G A G C A S Y		- RSTSQKSIV-	- AYTM - SLGA	684 69	7
ß		hSARS-CoV-HKU39849	638 647	P G A G C A S Y		- <mark>R S T S Q K SI V</mark> -	676	D S S AYSNNT AP 684	7
		Bat-SL-Rs4231	624 633	PGAGCASM		- <mark>R S T S Q K S I V</mark> -	- AYTM - SLGA	D S S AY S NNT A P 670 68	3
		Bat-SL-Rf1		P G A G C A S Y	HTASHE	- RSTGQKSIV-	- AYTM - SEGA	ENSVAYANNS A 671 68	4
		Bat-SL-HKU3-1		P G A G C A S M	HTASVL	- <mark>R S T</mark> G Q K S I V -	- AYTM - SE GA		3
		BtRs-BetaCoV/YN2018C	GAEHWNASY ECD	P G A G C A S Y	<mark>HTASTE</mark>	- <mark>R S M</mark> G <mark>Q K S I V</mark> -	- ATTM - SE GA	ENSTAYANNSTAT P	Ĺ
		Bat-SL-RS672	GAEHWNASY ECD			- <mark>R S V</mark> G Q K S I V -	- AYTM - SE GA		i i
		Bat-SL-Rs4255	624 GAEHWNASY ECD						3
	_	BtRs-BetaCoV/YN2018D	624 633		647		662	670 68	3
	В	Bat-SL-CoVZC45	629 638				667	675 68	8
			628 637	645	651	657	666	674 68	7
		Bat-SL-CoVZXC21	652 661	P G A G C A S Y	HTASIL	- RSTGQKATV-	690	ENSLAYANNSLAIP 698 71	1
		Bat-SL-RaTG13	652 661	P G A G C A S Y	<mark>QTQTNS</mark>	- R SVASQSIII -	694	NSVAYSNNSLAIP 702 71	5
		2019-nCoV-USA-CA1-ISL_406034	652 661	P G A G C A S Y	675	A R SVASQ SI I -	- AYTM - SEGA	ENSVAYSNNS AP 702 71	5
		2019-nCoV-Taiwan-EPI_ISL_406031		P G A G C A S Y	QTQTNSPRR		- AMTM - SE GA	NSVAYSNNS A 702 71	5
		2019-nCoV-Shenzhen-EPI_ISL_405839		P G A G C A S M	QTQTNSPRR		- AYTM - SE GA		5
		2019-nCoV-Nonthaburi-EPI_ISL_403962	GAEHWNNSY ECD	P G A G C A S Y	QTQTNSPRR	ARSMASQ SHI	ANTM - SEGA		į.
		2019-nCoV-Foshan-EPI-ISL-406534	GAEHWNNSM ECD	PIGAGICASY	QTQTNSPRR	ARSMASQSII	ATM-SCGA		į –
		2019-nCoV-Guangdong-EPI_ISL_406538			QTQTNSPRR	ARSMASQSIII -	- AMTM - SE GA		2
		2019-nCoV-Guangzhou-EPI_ISL_406533	652 GAEHWNNSY ECD			685 ARSVASOSILI-	694 - AYTM - SLGA	702 71 ENSVAYSNNS ALP	5
		2019-nCoV-Zhejiang-EPI_ISL_404228	652 661			685	694	702 71 ENSVAYSNNS A P	5
		2019-nCoV-France-EPI ISL 406596	652 661			685	694	702 71	5
			652 661	669	675	685	694	702 71	5
		2019-nCoV-Wuhan-WIV06-EPI_ISL_402129	652 661	P G A G C A S Y	675	A R S V A S Q S I I -	694	ENSVAYSNNSLATP 702 71	5
		2019-nCoV-Wuhan-Hu1	652 661	P G A G C A S Y	675	A R S M A S Q S I I -	694	EN SVAYSNNS A P 702 71	5
		2019-nCoV-USA-WA1-EPI_ISL_404895	GAEHMNNSM ECD	P G A G C A S Y	QTQTNSPRR	ARSVASQSIII-	- AYTM - SEGA	NSVAYSNNS A 702 71	5
		2019-nCoV-Foshan-EPI_ISL_406535		PIGAGICASM	OTQTNSPRR		- ATTM - SE GA		5
		2019-nCoV-USA-AZ1-ISL_406223		PIGAGICASY		ARSMASQ ST.	ANTM - SEGA		5
		2019-nCoV-USA-IL1-EPI_ISL_404253				ARSMASQ SIII -	- A YTM - SL GA		í.
			639 648	658		73		690 70	3
	D	BatCoV-HKU9	655 664	674	GSATANAD	92 92	701	T A T P M T P V Y W V K V P 707 72 72	0
		BatCoV-GCCDC1				SPNLLSLVV		G LKVLTPVYWVS IP	-
α		HCoV-229E	540 548	554 GMCADG	560 5 SI AVQ P R N	N	570 SYDS		


representatives of betacoronavirus lineages. The S protein sequence of 15 isolates of 2019-nCoV were aligned with representatives of all four *Betacoronavirus* lineages (lineages are denoted by the letters A, B, C, and D). The sequence for the *Alphacoronavirus* HCoV-229E is also included in the alignment. Displayed is the region corresponding to the S1/S2 cleavage site. Red border indicates the insert of basic arginines identified for 2019-nCoV sequences. α : *Alphacoronavirus*; β : *Betacoronavirus*. Accession numbers of sequences used in the analyses are found in the methods section.

Α


Amino acid identity

	HCoV-HKU1 S	MHV S	MERS-CoV S	SARS-CoV S
HCoV-HKU1 S		59.48 %	32.10 %	28.43 %
MHV S	59.48 %		29.35 %	28.25 %
MERS-CoV S	32.10 %	29.35 %		28.99 %
SARS-CoV S	28.25 %	28.25 %	28.99 %	

В



Supplementary figure 3. *Betacoronavirus* **S protein structures. A.** Amino acid identity table between Betacoronavirus S proteins. **B.** *Betacoronavirus* S protein structures: HCoV-HKU1, MHV, MERS-CoV and SARS-CoV.



Supplementary figure 4. 2019-nCoV S protein models based on *Betacoronavirus* structures. The 2019-nCoV S protein models were built based on the structure of HCoV-HKU1, MHV, MERS-CoV and SARS-CoV. The amino acid homology (red) and differences (blue) are noted. Amino acid identity scale is also shown.